Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 09/10/2024

    Language model "UroBot“ surpasses the accuracy of experienced urologists

    Scientists at the German Cancer Research Center (DKFZ), together with doctors from the Urological Clinic of the Mannheim University Hospital, have developed and successfully tested a chatbot based on artificial intelligence. "UroBot" was able to answer questions from the urology specialist examination with a high degree of accuracy, surpassing both other language models and the accuracy of experienced urologists.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/language-model-urobot-surpasses-accuracy-experienced-urologists
  • Press release - 08/07/2025

    Five million euros for research into early cancer detection

    Investing in a healthier future: The HORNBACH Group is supporting the new National Cancer Prevention Center in Heidelberg with a donation of five million euros. In the future, a new laboratory will conduct research into more effective early detection and screening methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-million-euros-research-early-cancer-detection
  • Press release - 01/02/2021

    Targeting a rapid market breakthrough for new vaccine production method

    In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
  • Press release - 13/04/2022

    Emmy Noether funding for research into drug resistance of blood cancer

    The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding a new Emmy Noether junior research group at the DKFZ for six years with a total of around 2 million euros. The scientists and doctors, who are part of the Clinical Cooperation Unit for Pediatric Leukemia at the KiTZ, are using a new procedure to investigate how cancer cells manipulate the formation of proteins to become resistant to cancer drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/emmy-noether-funding-research-drug-resistance-blood-cancer
  • Press release - 29/07/2022

    New centre for model-based artificial intelligence

    A centre for model-based artificial intelligence has been set up at Heidelberg University to link mathematical modelling methods with information processing in neuronal networks. The Carl Zeiss Foundation (CZS) is funding the CZS Heidelberg Center for Model-Based AI with five million euros over a period of six years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-centre-model-based-artificial-intelligence
  • Press release - 15/11/2024

    Selenium proteins as a possible new target for cancer research

    An important enzyme helps the body produce selenium proteins – this discovery could open up new strategies for treating cancer in children. This has been published by scientists from the University of Würzburg, the University Sao Paolo, the German Cancer Research Center (DKFZ) and the Heidelberg Stem Cell Institute HI-STEM*.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/selenium-proteins-possible-new-target-cancer-research
  • Press release - 05/08/2025

    Playing Dominos: how an artificial protein emerges from fitting together individual components

    The targeted engineering of artificial proteins with unique properties – that is possible with the assistance of a novel method developed by a research team of Heidelberg University. It centers around a new AI model. This allows for forecasting how two proteins have to be fitted together at the molecular level from individual parts – subunits – in order to engineer a functional, adjustable new protein.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/playing-dominos-how-artificial-protein-emerges-fitting-together-individual-components
  • Press release - 22/07/2026

    The Individual Genetic Background Shapes the Evolution of Cancer

    Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/individual-genetic-background-shapes-evolution-cancer
  • Press release - 22/05/2025

    Six Clusters of Excellence for the University of Tübingen

    Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/six-clusters-excellence-university-tubingen
  • Press release - 13/10/2021

    Tackling the collateral damage from antibiotics

    EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics
  • Press release - 19/03/2021

    New single-cell analysis of leucemic stem cells

    A new method allows stem cells and cancer stem cells to be studied at the single cell level and the resulting cell clones to be traced directly. Studying thousands of individual cells in parallel, the researchers combined the analysis of the genomic cancer mutations with the associated expression profiles.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-single-cell-analysis-leucemic-stem-cells
  • Press release - 21/04/2023

    New research building for engineering life-inspired molecular systems

    Heidelberg University is to acquire a research building to develop innovative engineering science strategies and technologies on the basis of life-inspired molecular systems. The German Science and Humanities Council has now expressed its backing for the idea with an outstanding rating. This recommendation is the crucial precondition for a new building on the university campus Im Neuenheimer Feld.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-building-engineering-life-inspired-molecular-systems
  • Press release - 05/06/2023

    New findings about human metabolic processes

    Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-about-human-metabolic-processes
  • Stem cell research - 14/03/2024 Image of red and blue coloured, round structures.

    Using organoids to gain a better clinical understanding of pancreatic cancer

    Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer
  • Press release - 03/07/2024

    CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

    CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-initiates-strategic-restructuring-align-resources-focus-high-value-mrna-pipeline-opportunities
  • Press release - 26/08/2024

    Synthetic Immunology: Approaching a Turning Point in the Treatment and Prevention of Disease

    Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/synthetic-immunology-approaching-turning-point-treatment-and-prevention-disease
  • Press release - 28/02/2025

    Early Excellence in Science Award für Ivana Winkler

    The Bayer Foundation's Early Excellence in Science Award 2024 in the category of Data Science goes to Ivana Winkler of the German Cancer Research Center (DKFZ). Winkler's work uncovered the unexpected effect of female reproductive capacity: the constantly recurring remodeling of the organs of the female reproductive tract during the sexual cycle leads to fibrosis and chronic inflammation over the years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-excellence-science-award-fuer-ivana-winkler
  • Press release - 06/03/2025

    New insights into the cellular mechanism of action of psilocybin

    A recent study by the Hector Institute for Translational Brain Research at the CIMH provides the first cellular insights into how psilocin promotes the growth and networking of human nerve cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-cellular-mechanism-action-psilocybin
  • Press release - 03/07/2025

    Focus on Muscle Metabolism: Sex Differences in Sport and Obesity

    The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/focus-muscle-metabolism-sex-differences-sport-and-obesity
  • Press release - 23/09/2025

    Not all ALK fusions act the same: Variants influence treatment success in lung cancer

    About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/not-all-alk-fusions-act-same-variants-influence-treatment-success-lung-cancer
  • Press release - 10/10/2025

    Acidic tumor environment promotes survival and growth of cancer cells

    Tumors are not a comfortable place to live: oxygen deficiency, nutrient scarcity, and the accumulation of sometimes harmful metabolic products constantly stress cancer cells. A research team from the DKFZ and the IMP in Vienna has now discovered that the acidic pH value in tumor tissue is a decisive factor in how pancreatic cancer cells adapt their energy metabolism in order to survive under these adverse conditions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/acidic-tumor-environment-promotes-survival-and-growth-cancer-cells
  • Press release - 24/11/2025

    Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich

    Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/shield-against-metastases-and-genetically-protected-car-t-cells-double-honor-mirco-julian-friedrich
  • Press release - 19/03/2026

    Carl-Zeiss-Stiftung Funds Pioneering AI Project at the DKFZ

    How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-stiftung-funds-pioneering-ai-project-dkfz
  • Press release - 25/03/2026

    The Influence of Lymph Node Architecture on Lymphoma

    For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the DKFZ, the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/influence-lymph-node-architecture-lymphoma
  • Press release - 21/05/2026

    Why pain persists long after injuries have healed

    Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the mechanisms underlying chronic pain be translated into new therapeutic approaches? These questions have been at the core of Rohini Kuner’s research for many years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-pain-persists-long-after-injuries-have-healed

Page 11 / 15

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search